Canaccord initiated coverage of Fractyl Health (GUTS) with a Buy rating and $12 price target Local administration to the pancreas combined with GLP-1 expression controlled by an insulin promoter means GLP-1 expression increases after food intake, the analyst tells investors in a research note. The firm believes Fractyl’s “Smart GLP-1” gene therapy platform Rejuva might be the solution. The company’s lead candidate RJVA-001 will enter clinical testing in type 2 diabetes in the first half of 2025, with initial data expected in 2026, notes Canaccord.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GUTS:
- Promising Potential for Fractyl Health, Inc. with Positive Early Data and Anticipated Insights
- Fractyl Health Reveals Promising Data on Revita Study
- Fractyl Health reports early data from REVEAL-1 cohort of REMAIN-1 study
- Fractyl Health’s Earnings Call: Progress Amid Challenges
- Fractyl Health Reports 2024 Financial Results and Strategic Progress